Figure 1.
Three examples of responses after intralesional rituximab. (A) Right eye: extensive infiltration of bulbar temporal conjunctiva of a lymphomatous mass with well-defined margins (arrows); the therapeutic target was well delimited. (C) Right eye: tumor infiltration of the inferior conjunctiva; the lesion of the bulbar conjunctiva was better defined (solid arrows), whereas infiltration of the palpebral conjunctiva was poorly delimited (open arrows). (E) Left eye: extensive infiltration of bulbar and palpebral inferior conjunctiva with intense hyperemia that hampered the definition of the borders of the lesion (open arrows) and required numerous subconjunctival injections of rituximab to avoid undertreatment. (B,D,F) Tumor regression after intralesional injections of rituximab.

Three examples of responses after intralesional rituximab. (A) Right eye: extensive infiltration of bulbar temporal conjunctiva of a lymphomatous mass with well-defined margins (arrows); the therapeutic target was well delimited. (C) Right eye: tumor infiltration of the inferior conjunctiva; the lesion of the bulbar conjunctiva was better defined (solid arrows), whereas infiltration of the palpebral conjunctiva was poorly delimited (open arrows). (E) Left eye: extensive infiltration of bulbar and palpebral inferior conjunctiva with intense hyperemia that hampered the definition of the borders of the lesion (open arrows) and required numerous subconjunctival injections of rituximab to avoid undertreatment. (B,D,F) Tumor regression after intralesional injections of rituximab.

Close Modal

or Create an Account

Close Modal
Close Modal